Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04017546
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
- Conditions
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04016805
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, New York, New York, United States
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedDiffuse Large B-Cell LymphomaDouble-Expressor LymphomaEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedNeoplastic Cells With Double Expression of MYC and BCL2 Proteins PresentTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: EtoposideProcedure: Lumbar PunctureProcedure: Positron Emission TomographyDrug: PrednisoneBiological: RituximabDrug: Vincristine SulfateDrug: Venetoclax
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 363
- Registration Number
- NCT03984448
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 50
- Registration Number
- NCT03980171
- Locations
- 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇦🇺Townsville Hospital and Health Services, Townsville, Queensland, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT03969446
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Sanjay Mohan
- Target Recruit Count
- 78
- Registration Number
- NCT03955783
- Locations
- 🇺🇸
Roswell Park Cancer Center, Buffalo, New York, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University Hospitals of Cleveland, Cleveland, Ohio, United States
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03946878
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
- Conditions
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Kerry Rogers
- Registration Number
- NCT03943342
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT03941964
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers /ID# 211508, Lone Tree, Colorado, United States
🇺🇸Tennessee Oncology - Chattanooga / McCallie /ID# 212717, Chattanooga, Tennessee, United States
🇺🇸Prisma Health Cancer Inst - Eastside /ID# 211466, Greenville, South Carolina, United States
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT03940352
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
🇺🇸Duke University Medical Center ., Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.